Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status.

Kitadai, Rui; Okuma, Yusuke; Kawai, Shoko

Kitadai, Rui; Okuma, Yusuke; Kawai, Shoko.

Afiliação

Kitadai R; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo 113-8677, Japan, y-okuma@cick.jp.
Okuma Y; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo 113-8677, Japan, y-okuma@cick.jp.
Kawai S; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo 113-8677, Japan, y-okuma@cick.jp.

Onco Targets Ther ; 12: 15-19, 2019.

Article em En | MEDLINE | ID: mdl-30588026

Palavras-chave

alectinib; anaplastic lymphoma kinase; ceritinib; non-small-cell lung cancer; poor performance status

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Onco Targets Ther Ano de publicação: 2019 Tipo de documento: Article